

Date: 30/05/2022

To

Dept. of Corporate Services,
Bombay Stock Exchange Limited,
Floor 25, P J Tower, Dalal Street,
Mumbai – 400001.

Scrip code: 526445

Dear Sir/Madam,

Sub: Outcome of the Board Meeting.

Ref: Regulation 33 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Please refer our letter dated May 23, 2022 under Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. In continuation, we wish to inform that at the meeting of Board of Directors held today i.e., on May 30, 2022, the Directors has inter-alia, amongst other subject approved the following:

- Audited financial results (standalone and consolidated) of the Company for the quarter and year ended March 31, 2022, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015.

We, herewith, have attached the declaration and the copy of the audited financial results (standalone and consolidated) for the quarter and year ended March 31, 2022 along with the Auditors report for the said period.

The Board Meeting commenced at 9.00 p.m. and concluded at 10.00 p.m. We are arranging to publish the audited financial results in the newspapers. The said financial results will also be available on company's website www.indrayani.com and also on BSE website www.bseindia.com.

We request you to take the same on record.

Thanking you,
Yours faithfully,

For Indrayani Biotech Limited



Vennila Vijayaragavan
Company Secretary & Compliance Officer



Encl: As above.

Date: 30/05/2022

To

Dept. of Corporate Services,
Bombay Stock Exchange Limited,
Floor 25, P J Tower, Dalal Street,
Mumbai – 400001.

Scrip code: 526445

Dear Sir/Madam,

Sub: Declaration pursuant to Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Ref: Unmodified opinion in the Auditors' Report for the FY 2021-22.

Pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby declare that M/s. Venkatesh & Co., the Statutory Auditors of the Company, have issued the Auditors' Report with unmodified opinion in respect to the Audited Financial Results (Standalone and Consolidated) of the Company for the financial year ended March 31, 2022.

We request you to take the same on record.

Thanking you,

Yours faithfully,

For Indrayani Biotech Limited


Vinayaka Bodala
Chief Financial Officer



INDRAYANI BIOTECH LIMITED

Regd. Office :

Block 1 Module No.33, 3rd Floor, SIDCO ELECTRONIC COMPLEX, THIRU VI KA INDUSTRIAL ESTATE, GUINDY
CHENNAI - 600032

STATEMENT OF FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31st MARCH 2022					
Rs. in Lakhs					
Sr No	PARTICULARS	STANDALONE			
		Quarter Ended		Year Ended	
		31-Mar-22	31-Dec-21	31-Mar-21	31-Mar-21
		Audited	Unaudited	Audited	Audited
1	Income from Operations				
	(a) Net Sales/Revenue from Operations	1,480.15	1,463.31	708.13	5,798.85
	(b) Other Income	0.57	15.29	14.75	22.08
	Total Income from Operations	1,480.72	1,478.59	722.88	5,820.94
2	Expenses				
	(a) Cost of Materials consumed	1,102.83	973.24	482.20	3,971.31
	(b) Changes in inventories of finished goods, work-in-progress and stock-in-trade				-
	(c) Employee benefits expenses	129.52	233.75	102.33	897.29
	(d) Finance Costs	43.55	59.27	100.25	187.97
	(e) Depreciation and amortisation expense	8.70	8.86	(24.53)	34.43
	(f) Other expenses	80.84	85.63	153.30	307.38
	Total Expenses	1,365.45	1,360.76	813.54	5,398.38
	Total profit / (Loss) before exceptional items and tax	115.27	117.83	(90.65)	422.56
3	Exceptional Items			(201.24)	(410.98)
4	Add: Share of Profit In Associates				
5	Total profit / (Loss) before tax	115.27	117.83	(291.89)	422.56
6	Total profit / (Loss) before tax				
7	Tax Expenses				
	Current Tax				
	Deferred Tax				
	Total Tax Expenses				
8	Net Profit Loss for the period from continuing operations	115.27	117.83	(291.89)	422.56
9	Profit (loss) from discontinued operations before tax				
10	Tax expense of discontinued operations				
11	Net profit (loss) from discontinued operation after tax				
12	Share of profit (loss) of associates and joint ventures accounted for using equity method				
13	Total profit (loss) for period	115.27	117.83	(291.89)	422.56
14	Other comprehensive income net of taxes				
15	Total Comprehensive income for the period attributable to	115.27	117.83	(291.89)	422.56
	Comprehensive income for the period attributable to owners of parent	115.27	117.83	(291.89)	422.56
	Total comprehensive income for the period attributable to owners of parent noncontrolling interests				

For INDRAYANI BIOTECH LIMITED




K. durgam Reddy
Managing Director

16	Details of equity share capital					
	Paid-up equity share capital	3,422.72	3,422.72	3,422.72	3,422.72	3,422.72
	Face value of equity share capital(Rs.)	10.00	10.00	10.00	10.00	10.00
17	Details of debt securities					
	Paid-up debt capital					
	Face value of debt securities					
18	Reserves excluding revaluation reserve					
19	Debenture redemption reserve					
20	Earnings per share					
i	Earnings per equity share for continuing operations	0.34	0.34	(0.85)	1.23	(3.18)
	Basic earnings (loss) per share from continuing operations	0.34	0.34	(0.85)	1.23	(3.18)
	Diluted earnings (loss) per share from continuing operations					
ii	Earnings per equity share for discontinued operations					
	Basic earnings (loss) per share from discontinued operations					
	Diluted earnings (loss) per share from discontinued operations					
iii	Earnings per equity share					
	Basic earnings (loss) per share from continuing and discontinued operations	0.34	0.34	(0.85)	1.23	(3.18)
	Diluted earnings (loss) per share from continuing and discontinued operations	0.34	0.34	(0.85)	1.23	(3.18)
Notes: 1. The Standalone financial results are being forwarded to the Bombay Stock Exchanges (BSE & PSE)om)& also available on the company website (www.indrayani.com for uploading on the respective websites and are also available on the Company's website (www.indrayani.com). 2. The above audited financial results have been reviewed by the Audit Committee and approved by the Board of Directors in the meeting held on 30-05-2022. The above financial results are subject to audited by the Statutory Auditors of the Company. 3. The figures of the last quarter(s) are the balancing figures between audited figures in respect of the full financial year(s) and published figures up to the quarter ended 31st December of the current and previous period 6. There were no investor complaints pending at the beginning or at the end of the quarter. No compliants were received during the quarter. 5. Previous period figures have been regrouped wherever necessary. Date : 30/05/2022 Place : Chennai						

For INDRAYANI BIOTECH LIMITED

K. durgam
Managing Director



M/s. INDRAYANI BIOTECH LIMITED		
CIN : L40100TN1992PLC129301		
BLOCK I, MODULE NO.33, 3rd FLOOR, SIDCO ELECTRONIC COMPLEX, THIRU VI KA INDUSTRIAL ESTATE, GUINDY, CHENNAI, 600032		
Standalone Statement of Assets and Liabilities	Amount (Rs.in Lakh)	
Particulars	As at 31.03.2022	As at 31-03-2021
ASSETS		
A) Non - Current Assets		
a) Property Plant and Equipment	1,149	1,128
c) Capital Work in Progress	1,322	1,372
d) Goodwill	384	384
e) Other Intangible assets		
f) Financial Assets		
--- (i) Investments	19	19
--- (ii) Other Financial Assets		
g) Other Non Current assets	68	133
B) Current Assets		
a) Inventories	137	108
b) Financial Assets		
--- (i) Investments		
--- (ii) Trade Receivables	1,288	477
--- (iii) Cash and cash Equivalents	145	63
--- (iii) Other Financial Assets	90	47
c) Other Current assets	343	256
Total Assets	4,943	3,985
EQUITY & LIABILITIES		
A) Equity		
a) Equity Share Capital	3,423	3,423
b) Other Equity	-1,006	-1,428
B) LIABILITIES		
Non - Current Liabilities		
a) Financial Liabilities		
--- (i) Borrowings	679	815
--- (ii) Other financial Liabilities		
b) Deferred Tax Liabilities	1	1
c) Other Non Current Liabilities		
Current Liabilities		
a) Financial Liabilities		
--- (i) Short Term Borrowings	995	728
--- (ii) Trade Payables		
----- (A) total outstanding dues of micro enterprises and small enterprises;		
----- (B) total outstanding dues of creditors other than micro enterprises and small enterprises	645	342
--- (iii) Other financial Liabilities		
b) Other Current Liabilities	74	18
c) Provisions	132	85
Total Equity & Liabilities	4,943	3,985

For INDRAYANI BIOTECH LIMITED



K. durganand

Managing Director

M/s. INDRAYANI BIOTECH LIMITED
BLOCK I, MODULE NO.33, 3rd FLOOR, SIDCO ELECTRONIC COMPLEX, THIRU VI KA INDUSTRIAL ESTATE,
GUINDY, CHENNAI, 600032

CIN : L40100TN1992PLC129301

Audited Standalone Statement of Cash Flow		Amount (Rs.in Lakh)	
Particulars	As on 31-Mar-22	As on 31-Mar-21	
Cash Flows From Operating Activities:-			
Net Profit after Taxation	423	(1,089)	
Adjustment for Non cash items			
Add : Impairment of Fixed Assets		210	
Add : Depreciation	34	40	
Less : Interest Income Notional (As per Ind AS 109)	(1)	(2)	
Add : Notional Rent as per IND AS		3	
Adjustment for Non Operating activities			
Add : Interest Paid	188	196	
Less : Interest income		-	
Cash Flow Before Working Capital changes:-	643	(642)	
Decrease (Increase) in Inventories	(28)	399	
Decrease (Increase) in Trade receivables	(811)	228	
Decrease (Increase) in other current assets	(131)	262	
(Decrease) Increase in Short term borrowings	267	48	
(Decrease) Increase in Trade payables	303	(284)	
(Decrease) Increase in Other Current liabilities	56	(31)	
(Decrease) Increase in Provisions	47	71	
Cash Flow Before Tax and Extraordinary Items:-			
Income Taxes Paid	-	-	
Net Cash Flow From Operating Activities	347	52	
Cash Flow from Investing Activities:-			
Less : Purchase of Capital Assets	(6)	(38)	
Less : Purchase of Investments	-	(17)	
Add : Rental Receipts		-	
Add : Amount of Interest Received		-	
Less : Sale of Capital Assets		1	
Decrease (Increase) in Loans and advances & Other assets	65	(2)	
Net Cash flow used in Investing Activities	59	(56)	
Cash Flow from Financing Activities:-			
Increase in Borrowings			
Interest Income Notional (As per Ind AS 109)	1	2	
Increase in Share capital			
Increase in Other Non current liabilities			
Interest expense	(188)	(196)	
Decrease in borrowings	(137)	121	
Net Cash Flow From Financing Activities	(323)	(73)	
Net Increase/(Decrease) in Cash and Cash Equivalents:-			
(Opening Balance)	63	140	
Net Cash Flow during the year	82	(78)	
(Closing Balance)	145	63	

For INDRAYANI BIOTECH LIMITED

K. Arun Kumar

Managing Director





VENKATESH & CO
Chartered Accountants

Independent Auditor's Report on Quarterly Financial Results and Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

**To The Board of Directors of
Indrayani Biotech Limited
Chennai**

Report on the Audit of the standalone financial results

Opinion

We have audited the quarterly financial results of **Indrayani Biotech Limited** for the quarter ended **31st March, 2022** and the year to date results for the period **01st April, 2021 to 31st March, 2022**, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as Amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results as well as the year to date results:

- i. are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard;
- ii. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India of the net Loss and other comprehensive income and other financial information for the quarter ended **31st March, 2022** as well as the year to date results for the period from **01st April, 2021 to 31st March, 2022**

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion

Management's Responsibilities for the Standalone Financial Results

These quarterly financial results as well as the year to date standalone financial results have been prepared on the basis of the interim financial statements. The Company's Board of Directors are responsible for the preparation of these financial results that give a true and fair view of the net Loss and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim



"SRI RANGA", New No.151, Mambalam High Road, T.Nagar, Chennai - 600 017.

Telefax : 2814 4763/64/65/66 Email : venkateshandco@gmail.com



VENKATESH & CO

Chartered Accountants

Financial Reporting' prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.



"SRI RANGA", New No.151, Mambalam High Road, T.Nagar, Chennai - 600 017.

Telefax : 2814 4763/64/65/66 Email : venkateshandco@gmail.com



VENKATESH & CO


Chartered Accountants

- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards

For Venkatesh & Co
Chartered Accountants
F.R.No.004636S


CA Dasaraty V

Partner
M.No.026336



Place: Chennai
Date: 30/05/2022
UDIN: 22026336AJXXHG2149

INDRAYANI BIOTECH LIMITED						
Regd. Office :						
Block 1 Module No.33, 3rd Floor,SIDCO ELECTRONIC COMPLEX, THIRU VI KA INDUSTRIAL ESTATE,GUINDY						
CHENNAI - 600032						
STATEMENT OF FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31st MARCH 2022						
Rs. In Lakhs						
		CONSOLIDATED				
		Quarter Ended			Year Ended	
Sr No	PARTICULARS	31-Mar-22	31-Dec-21	31-Mar-21	31-Mar-22	31-Mar-21
		Audited	Unaudited	Audited	Audited	Audited
1	Income from Operations					
	(a) Net Sales/Revenue from Operations	1,724.67	1,525.06	716.24	6,157.18	2,108.84
	(b) Other Income	0.54	15.29	14.91	22.08	26.50
	Total Income from Operations	1,725.21	1,540.35	731.15	6,179.26	2,135.34
2	Expenses					
	(a) Cost of Materials consumed	1,223.26	979.47	483.45	4,104.29	1,577.15
	(b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-
	(c) Employee benefits expenses	180.97	266.72	125.53	1,021.64	594.40
	(d) Finance Costs	43.55	59.27	100.25	187.97	196.14
	(e) Depreciation and amortisation expense	17.87	26.69	(18.96)	65.94	45.82
	(f) Other expenses	96.57	93.45	164.58	354.23	432.56
	Total Expenses	1,562.23	1,425.60	854.85	5,734.07	2,846.08
	Total profit / (Loss) before exceptional items and tax	162.98	114.75	(123.70)	445.19	(710.74)
3	Exceptional Items	-	-	(201.24)	-	(410.98)
	Add:Share of Profit In Associates	(0.85)	(0.21)	0.28	-	0.28
5	Total profit / (Loss) before tax	162.13	114.53	(324.66)	445.19	(1,121.44)
6	Total profit / (Loss) before tax					
7	Tax Expenses	1.24		-	1.24	
	Current Tax					
	Deferred Tax					
	Total Tax Expenses					
	Net Profit Loss for the period from continuing operations	160.89	114.53	(324.66)	443.95	(1,121.44)
9	Profit (loss) from discontinued operations before tax					
10	Tax expense of discontinued operations					
	Net profit (loss) from discontinued operation after tax					
12	Share of profit (loss) of associates and joint ventures accounted for using equity method					
13	Total profit (loss) for period	160.89	114.53	(324.66)	443.95	(1,121.44)

For INDRAYANI BIOTECH LIMITED

K. durganand
Managing Director



14	Other comprehensive income net of taxes					
15	Total Comprehensive income for the period attributable to	160.89	114.53	(324.66)	443.95	(1,121.44)
	Comprehensive income for the period attributable to owners of parent	150.72	118.37	(315.37)	442.75	(1,112.15)
	Total comprehensive income for the period attributable to owners of parent noncontrolling interests	10.17	(3.83)	(9.29)	1.20	(9.29)
16	Details of equity share capital					
	Paid-up equity share capital	3,422.72	3,422.72	3,422.72	3,422.72	3,422.72
	Face value of equity share capital(Rs.)	10.00	10.00	10.00	10.00	10.00
17	Details of debt securities					
	Paid-up debt capital					
	Face value of debt securities					
18	Reserves excluding revaluation reserve					
19	Debenture redemption reserve					
20	Earnings per share					
i	Earnings per equity share for continuing operations	0.47	0.33	(0.92)	1.30	(3.15)
	Basic earnings (loss) per share from continuing operations	0.47	0.33	(0.92)	1.30	(3.15)
	Diluted earnings (loss) per share from continuing operations					
ii	Earnings per equity share for discontinued operations					
	Basic earnings (loss) per share from discontinued operations					
	Diluted earnings (loss) per share from discontinued operations					
iii	Earnings per equity share					
	Basic earnings (loss) per share from continuing and discontinued operations	0.47	0.33	(0.92)	1.30	(3.15)
	Diluted earnings (loss) per share from continuing and discontinued operations	0.47	0.33	(0.92)	1.30	(3.15)
Notes: 1.The Consolidated financial results are being forwarded to the Bombay Stock Exchanges (BSE & PSE)om)& also available on the company website (www.indrayani.com for uploading on the respective websites and are also available on the Company's website (www.indrayani.com). 2. The above audited financial results have been reviewed by the Audit Committee and approved by the Board of Directors in the meeting held on 30-05-2022. The above financial results are subject to audited by the Statutory Auditors of the Company. 3.The figures of the last quarter(s) are the balancing figures between audited figures in respect of the full financial year(s) and published figures up to the quarter ended 31st December of the current and previous period 4. There were no investor complaints pending at the beginning or at the end of the quarter. No compliants were received during the quarter. 5. Previous period figures have been regrouped wherever necessary. Date : 30/05/2022 Place : Chennai						

For INDRAYANI BIOTECH LIMITED

K. Arun Kumar
Managing Director



M/s. INDRAYANI BIOTECH LIMITED
BLOCK I, MODULE NO.33, 3rd FLOOR, SIDCO ELECTRONIC COMPLEX, THIRU VI
KA INDUSTRIAL ESTATE, GUINDY, CHENNAI, 600032
CIN : L40100TN1992PLC129301

Rs. In Lakh

Consolidated Balance sheet as at 31st March 2022

Particulars	31-03-2022	31-03-2021
ASSETS		
A) Non - Current Assets		
a) Property Plant and Equipment	1,267	1,153
b) Capital Work in Progress	1,327	1,372
c) Goodwill	384	384
d) Other Intangible assets		
e) Financial Assets		
--- (i) Investments	0	1
--- (ii) Other Financial Assets		
f) Other Non Current assets	68	133
B) Current Assets		
a) Inventories	153	109
b) Financial Assets		
--- (i) Investments		
--- (ii) Trade Receivables	1,410	477
--- (iii) Cash and cash Equivalents	150	68
--- (iv) Other Financial Assets	90	47
c) Other Current assets	291	262
Total Assets	5,140	4,005
EQUITY & LIABILITIES		
A) Equity		
a) Equity Share Capital	3,423	3,423
b) Other Equity	-1,006	-1,451
b) Non Controlling Interest within Equity	41	36
B) LIABILITIES		
Non - Current Liabilities		
a) Financial Liabilities		
--- (i) Borrowings	679	815
--- (ia) Lease liabilities	55	
--- (ii) Other financial Liabilities		
b) Deferred Tax Liabilities	1	1
c) Other Non Current Liabilities		
Current Liabilities		
a) Financial Liabilities		
--- (i) Short Term Borrowings	1,110	738
--- (i) Lease Liabilities	36	
--- (ii) Trade Payables		
----- (A) total outstanding dues of micro enterprises and small enterprises;		
----- (B) total outstanding dues of creditors other than micro enterprises and small enterprises	582	334
--- (iii) Other financial Liabilities		
b) Other Current Liabilities	72	18
c) Provisions	148	91
Total Equity & Liabilities	5,140	4,005

For INDRAYANI BIOTECH LIMITED

K. dhanu

Managing Director



M/s. INDRAYANI BIOTECH LIMITED
BLOCK I, MODULE NO.33, 3rd FLOOR, SIDCO ELECTRONIC COMPLEX, THIRU VI KA INDUSTRIAL
ESTATE, GUINDY, CHENNAI, 600032

CIN : L40100TN1992PLC129301

Consolidated Statement of Cash Flows for the year ended 31st March 2022

Particulars	Rs.in Lakh	
	As on 31-Mar-22	As on 31-Mar-21
Cash Flows From Operating Activities:-		
Net Profit after Taxation	444	-1,121
Adjustment for Non cash items		
Add : Impairment of Fixed Assets		210
Add : Depreciation	66	46
Less : Interest Income Notional (As per Ind AS 109)	-1	-2
Add : Notional Rent as per IND AS		3
Less: Share of profit of Associates		0
Adjustment for Non Operating activities		
Add : Interest Paid	188	196
Less : Interest income	-	-
Cash Flow Before Working Capital changes:-	696	(669)
Decrease (Increase) in Inventories	-44	398
Decrease (Increase) in Trade receivables	-933	228
Decrease (Increase) in other current assets	-72	256
(Decrease) Increase in Short term borrowings	369	58
(Decrease) Increase in Lease Liabilities	36	
(Decrease) Increase in Trade payables	248	-292
(Decrease) Increase in Other Current liabilities	54	-31
(Decrease) Increase in Provisions	58	77
Cash Flow Before Tax and Extraordinary Items:-		
Income Taxes Paid		
Net Cash Flow From Operating Activities	411	26
Cash Flow from Investing Activities:-		
Less : Purchase of Capital Assets	-119	-70
Less : Purchase of Investments		
Add : Goodwill on Consolidation	-2	0
Add : Amount of Interest Received		
Less : Sale of Capital Assets	-	1
Decrease (Increase) in Loans and advances & Other assets	65	-2
Net Cash flow used in Investing Activities	(56)	(70)
Cash Flow from Financing Activities:-		
Increase in Borrowings		
Increase in Lease Liabilities	55	-
Interest Income Notional (As per Ind AS 109)	1	2
Increase in Non Controlling interest	-5	45
Increase in Other Non current liabilities		
Interest expense	-188	-196
Decrease in borrowings	-137	121
Net Cash Flow From Financing Activities	(273)	(28)
Net Increase/(Decrease) in Cash and Cash Equivalents:-		
(Opening Balance)	68	140
Net Cash Flow during the year	82	-72
(Closing Balance)	150	68

For INDRAYANI BIOTECH LIMITED

K. durga dhar

Managing Director





VENKATESH & CO

Chartered Accountants

Independent Auditor's Report On consolidated audited quarterly and year to date financial results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

**To the Board of Directors of
Indrayani Biotech Limited
Chennai**

Report on the audit of the Consolidated Financial Results

Opinion

We have audited the accompanying Statement of Consolidated Financial Results of **Indrayani Biotech Limited** (Holding company) and its subsidiaries (holding company and its subsidiaries together referred to as "the Group"), its associates and jointly controlled entities for the quarter ended **31st March 2022** and for the period from **01st April 2021 to 31st March 2022** (the Statement), being submitted by the holding company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). Attention is drawn to the fact that the consolidated figures for the corresponding quarter ended **31st March 2022** and the corresponding period from **01st April 2021 to 31st March 2022** as reported in these financial results have been approved by the holding company's Board of Directors, but have not been subjected to audit/review.

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of the reports of the other auditors on separate financial statements/ financial information of subsidiaries, associates and jointly controlled entities, the Statement:

a. includes the results of the following entities:

- i) HSL Agri Solutions Private Limited – Subsidiary
- ii) TBL Healthcare Private Limited – Subsidiary
- iii) IBL Thiruvannamalai LLP _ Step down Subsidiary
- iv) HSL Prime Properties Private Limited - Subsidiary

is presented in accordance with the requirements of Regulation 33 of the Listing Regulations, as amended; and

b. gives a true and fair view, in conformity with the applicable accounting standards, and other accounting principles generally accepted in India, of consolidated total comprehensive income (comprising of net profit and other comprehensive income(loss)) and other financial information of the Group for the quarter ended **31st March 2022** and for the period from **01st April 2021 to 31st March 2022**

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Consolidated Financial Results* section of our report. We are independent of the Group, its associates and jointly controlled entities in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical





VENKATESH & CO

Chartered Accountants

responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us and other auditors in terms of their reports referred to in "Other Matter" paragraph below, is sufficient and appropriate to provide a basis for our opinion.

Management's Responsibilities for the Consolidated Financial Results

These quarterly financial results as well as the year to date consolidated financial results have been prepared on the basis of the interim financial statements.

The Holding Company's Board of Directors are responsible for the preparation and presentation of these consolidated financial results that give a true and fair view of the net profit/ loss and other comprehensive income and other financial information of the Group including its associates and jointly controlled entities in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting' prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The respective Board of Directors of the companies included in the Group and of its associates and jointly controlled entities are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and its associates and jointly controlled entities and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated financial results by the Directors of the Holding Company, as aforesaid.

In preparing the consolidated financial results, the respective Board of Directors of the companies included in the Group and of its associates and jointly controlled entities are responsible for assessing the ability of the Group and of its associates and jointly controlled entities to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group and of its associates and jointly controlled entities are responsible for overseeing the financial reporting process of the Group and of its associates and jointly controlled entities.

Auditor's Responsibilities for the Audit of the Consolidated Financial Results

Our objectives are to obtain reasonable assurance about whether the consolidated financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:





VENKATESH & CO

Chartered Accountants

- Identify and assess the risks of material misstatement of the consolidated financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group and its associates and jointly controlled entities to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group and its associates and jointly controlled entities to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial results, including the disclosures, and whether the consolidated financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial results/financial information of the entities within the Group and its associates and jointly controlled entities to express an opinion on the consolidated Financial Results. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the consolidated financial results of which we are the independent auditors. For the other entities included in the consolidated Financial Results, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

We communicate with those charged with governance of the Holding Company and such other entities included in the consolidated financial results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matters

- a) The consolidated Financial Results include the audited Financial Results of 4 Subsidiaries whose Financial Statements reflect Group's share of total assets of Rs 413 Lakhs as at **31st March 2022**, Group's share of total revenue of Rs 659 Lakhs and Group's share of total net profit/(Loss) after tax of Rs 21.40 Lakhs respectively for the period from **01st April 2021 to**





VENKATESH & CO

Chartered Accountants

31st March 2022 as considered in the consolidated Financial Results, which have been audited by their respective independent auditors. The independent auditors' reports on interim financial statements/Financial Results/financial information of these entities have been furnished to us and our opinion on the consolidated Financial Results, in so far as it relates to the amounts and disclosures Included In respect of these entities, is based solely on the report of such auditors and the procedures performed by us are as stated in paragraph above.

- b) Further out of the subsidiaries mentioned in point (a) above, we did not audit the statements of **2** subsidiaries, whose financial statements reflect total assets of Rs 255 Lakhs as at March 31, 2022, total revenues of Rs.353.83 Lakhs, total comprehensive income of Rs 17.87 Lakhs for the year ended on that date, as considered in the Statement. These financial statements have not audited and been certified by the management. Our opinion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based on the management certified financial statements.

Our opinion on the consolidated Financial Results is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors and the Financial Results/financial information certified by the Board of Directors.

For Venkatesh & Co
Chartered Accountants
F.R.No.004636S

CA Dasaraty V
Partner

M.No.026336

Date: 30/05/2022

Place: Chennai

UDIN: 22026336AJXXNF6743

